RESUMEN
Phase-amplitude coupling (PAC) is proposed to play an essential role in coordinating the processing of information on local and global scales. In recent years, the methods able to reveal trustworthy PAC has gained considerable interest. However, the intrinsic features of some signals can lead to the identification of spurious or waveform-dependent coupling. This prompted us to develop an easily accessible tool that could be used to differentiate spurious from authentic PAC. Here, we propose a new tool for more reliable detection of PAC named the Extended Modulation Index (eMI) based on the classical Modulation Index measure of coupling. eMI is suitable both for continuous and epoched data and allows estimation of the statistical significance of each pair of frequencies for phase and for amplitude in the whole comodulogram in the framework of extreme value statistics. We compared eMI with the reference PAC measures-direct PAC estimator (a modification of Mean Vector Length) and standard Modulation Index. All three methods were tested using computer-simulated data and actual local field potential recordings from freely moving rats. All methods exhibited similar properties in terms of sensitivity and specificity of PAC detection. eMI proved to be more selective in the dimension of frequency for phase. One of the novelty's offered by eMI is a heuristic algorithm for classification of PAC as Reliable or Ambiguous. It relies on analysis of the relation between the spectral properties of the signal and the detected coupling. Moreover, eMI generates visualizations that support further evaluation of the coupling properties. It also introduces the concept of the polar phase-histogram to study phase relations of coupled slow and fast oscillations. We discuss the extent to which eMI addresses the known problems of interpreting PAC. The Matlab® toolbox implementing eMI framework, and the two reference PAC estimators is freely available as EEGLAB plugin at https://github.com/GabrielaJurkiewicz/ePAC .
Asunto(s)
Potenciales de Acción/fisiología , Algoritmos , Encéfalo/fisiología , Simulación por Computador , Procesamiento de Señales Asistido por Computador , Animales , Masculino , Modelos Neurológicos , Distribución Normal , RatasRESUMEN
BACKGROUND: An emerging problem in the treatment of breast cancer is the increasing incidence of metastases to the brain. Metastatic brain tumours are incurable and can cause epileptic seizures and cognitive impairment, so better understanding of this niche, and the cellular mechanisms, is urgently required. Microglia are the resident brain macrophage population, becoming "activated" by neuronal injury, eliciting an inflammatory response. Microglia promote proliferation, angiogenesis and invasion in brain tumours and metastases. However, the mechanisms underlying microglial involvement appear complex and better models are required to improve understanding of function. METHODS: Here, we sought to address this need by developing a model to study metastatic breast cancer cell-microglial interactions using intravital imaging combined with ex vivo electrophysiology. We implanted an optical window on the parietal bone to facilitate observation of cellular behaviour in situ in the outer cortex of heterozygous Cx3cr1GFP/+ mice. RESULTS: We detected GFP-expressing microglia in Cx3cr1GFP/+ mice up to 350 µm below the window without significant loss of resolution. When DsRed-expressing metastatic MDA-MB-231 breast cancer cells were implanted in Matrigel under the optical window, significant accumulation of activated microglia around invading tumour cells could be observed. This inflammatory response resulted in significant cortical disorganisation and aberrant spontaneously-occurring local field potential spike events around the metastatic site. CONCLUSIONS: These data suggest that peritumoral microglial activation and accumulation may play a critical role in local tissue changes underpinning aberrant cortical activity, which offers a possible mechanism for the disrupted cognitive performance and seizures seen in patients with metastatic breast cancer.
Asunto(s)
Neoplasias Encefálicas/secundario , Neoplasias de la Mama/patología , Modelos Animales de Enfermedad , Microscopía Intravital/métodos , Microglía , Animales , Línea Celular Tumoral , Femenino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Microambiente Tumoral/fisiologíaRESUMEN
Brain dynamic changes associated with schizophrenia are largely equivocal, with interpretation complicated by many factors, such as the presence of therapeutic agents and the complex nature of the syndrome itself. Evidence for a brain-wide change in individual network oscillations, shared by all patients, is largely equivocal, but stronger for lower (delta) than for higher (gamma) bands. However, region-specific changes in rhythms across multiple, interdependent, nested frequencies may correlate better with pathology. Changes in synaptic excitation and inhibition in schizophrenia disrupt delta rhythm-mediated cortico-cortical communication, while enhancing thalamocortical communication in this frequency band. The contrasting relationships between delta and higher frequencies in thalamus and cortex generate frequency mismatches in inter-regional connectivity, leading to a disruption in temporal communication between higher-order brain regions associated with mental time travel.
Asunto(s)
Encéfalo/fisiopatología , Esquizofrenia/fisiopatología , Animales , Ondas Encefálicas/fisiología , Humanos , Vías Nerviosas/fisiopatologíaRESUMEN
RATIONALE: Abnormal oscillatory activity associated with N-methyl-D-aspartate (NMDA) receptor hypofunction is widely considered to contribute to the symptoms of schizophrenia. OBJECTIVE: This study aims to characterise the changes produced by NMDA receptor antagonists and antipsychotics on accumbal high-frequency oscillations (HFO; 130-180 Hz) in mice. METHODS: Local field potentials were recorded from the nucleus accumbens of freely moving mice. RESULTS: Systemic injection of ketamine and MK801 both dose-dependently increased the power of HFO and produced small increases in HFO frequency. The atypical antipsychotic drug, clozapine, produced a robust dose-dependent reduction in the frequency of MK801-enhanced HFO, whilst haloperidol, a typical antipsychotic drug, had little effect. Stimulation of NMDA receptors (directly or through the glycine site) as well as activation of 5-HT1A receptors, reduced the frequency of MK801-enhanced HFO, but other receptors known to be targets for clozapine, namely 5-HT2A, 5-HT7 and histamine H3 receptors had no effect. CONCLUSIONS: NMDA receptor antagonists and antipsychotics produce broadly similar fundamental effects on HFO, as reported previously for rats, but we did observe several notable differences. In mice, HFO at baseline were weak or not detectable unlike rats. Post-injection of NMDA receptor antagonists HFO was also weaker but significantly faster. Additionally, we found that atypical antipsychotic drugs may reduce the frequency of HFO by interacting with NMDA and/or 5-HT1A receptors.
Asunto(s)
Antipsicóticos/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Núcleo Accumbens/efectos de los fármacos , Animales , Clozapina/farmacología , Maleato de Dizocilpina/farmacología , Relación Dosis-Respuesta a Droga , Haloperidol/farmacología , Ketamina/farmacología , Masculino , Ratones , Ratas Wistar , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidoresRESUMEN
BACKGROUND: Altered activity of the nucleus accumbens (NAc) is thought to be a core feature of schizophrenia and animal models of the disease. Abnormal high frequency oscillations (HFO) in the rat NAc have been associated with pharmacological models of schizophrenia, in particular the N-methyl-d-aspartate receptor (NMDAR) hypofunction model. Here, we tested the hypothesis that abnormal HFO are also associated with a neurodevelopmental rat model. METHODS: Using prenatal administration of the mitotoxin methylazoxymethanol acetate (MAM) we obtained the offspring MAM rats. Adult MAM and Sham rats were implanted with electrodes, for local field potential recordings, in the NAc. RESULTS: Spontaneous HFO (spHFO) in MAM rats were characterized by increased power and frequency relative to Sham rats. MK801 dose-dependently increased the power of HFO in both groups. However, the dose-dependent increase in HFO frequency found in Sham rats was occluded in MAM rats. The antipsychotic compound, clozapine reduced the frequency of HFO which was similar in both MAM and Sham rats. Further, HFO were modulated in a similar manner by delta oscillations in both MAM and Sham rats. CONCLUSION: Together these findings suggest that increased HFO frequency represents an important feature in certain animal models of schizophrenia. These findings support the hypothesis that altered functioning of the NAc is a core feature in animal models of schizophrenia.
Asunto(s)
Ondas Encefálicas/fisiología , Acetato de Metilazoximetanol/toxicidad , Neurotoxinas/toxicidad , Núcleo Accumbens/fisiopatología , Esquizofrenia/inducido químicamente , Esquizofrenia/patología , Animales , Antipsicóticos/farmacología , Ondas Encefálicas/efectos de los fármacos , Clozapina/farmacología , Modelos Animales de Enfermedad , Maleato de Dizocilpina/farmacología , Relación Dosis-Respuesta a Droga , Electroencefalografía , Potenciales Evocados/efectos de los fármacos , Potenciales Evocados/fisiología , Antagonistas de Aminoácidos Excitadores , Femenino , Masculino , Núcleo Accumbens/efectos de los fármacos , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Ratas , Ratas Wistar , Esquizofrenia/tratamiento farmacológicoRESUMEN
Distinct frequency bands can be differentiated from neuronal ensemble recordings, such as local field potentials or electrocorticogram recordings. Recent years have witnessed a rapid acceleration of research examining how N-methyl-D-aspartate receptor (NMDAR) antagonists influence fundamental frequency bands in cortical and subcortical brain regions. Herein, we systematically review findings from in vivo studies with a focus on delta, theta, gamma and more recently identified high-frequency oscillations. We also discuss some of the current hypotheses that are considered to account for the actions of NMDAR antagonists on these frequency bands. The data emphasize a close relationship between altered oscillatory activity and NMDAR blockade, with both local and large-scale networks accounting for their effects. These findings may have fundamental implications for the psychotomimetic effects produced by NMDAR antagonists.
Asunto(s)
Ondas Encefálicas/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Animales , Ondas Encefálicas/fisiología , Receptores de N-Metil-D-Aspartato/fisiologíaRESUMEN
RATIONALE: The nucleus accumbens (NAc) is a site critical for the actions of many drugs of abuse. Psychoactive compounds, such as N-methyl-D-aspartate receptor (NMDAR) antagonists, modify gamma (40-90) and high frequency oscillations (HFO, 130-180 Hz) in local field potentials (LFPs) recorded in the NAc. Lysergic acid diethylamide (LSD) and 2,5-dimethoxy-4-iodoamphetamine (DOI) are serotonergic hallucinogens and activation of 5HT2A receptors likely underlies their hallucinogenic effects. Whether these compounds can also modulate LFP oscillations in the NAc is unclear. OBJECTIVE: This study aims to examine the effect of serotonergic hallucinogens on gamma and HFO recorded in the NAc and to test whether 5HT2A receptors mediate the effects observed. METHODS: LFPs were recorded from the NAc of freely moving rats. Drugs were administered intraperitoneally. RESULTS: LSD (0.03-0.3 mg/kg) and DOI (0.5-2.0 mg/kg) increased the power and reduced the frequency of HFO. In contrast, the hallucinogens produced a robust reduction in the power of low (40-60 Hz), but not high gamma oscillations (70-90 Hz). MDL 11939 (1.0 mg/kg), a 5HT2A receptor antagonist, fully reversed the changes induced by DOI on HFO but only partially for the low gamma band. Equivalent increases in HFO power were observed after TCB-2 (5HT2A receptor agonist, 0.1-1.5 mg/kg), but not CP 809101 (5H2C receptor agonist, 0.1-3 mg/kg). Notably, hallucinogen-induced increases in HFO power were smaller than those produced by ketamine (25 mg/kg). CONCLUSIONS: Serotonergic hallucinogen-induced changes in HFO and gamma are mediated, at least in part, by stimulation of 5HT2A receptors. Comparison of the oscillatory changes produced by serotonergic hallucinogens and NMDAR antagonists are also discussed.
Asunto(s)
Anfetaminas/farmacología , Alucinógenos/farmacología , Dietilamida del Ácido Lisérgico/farmacología , Receptor de Serotonina 5-HT2A/efectos de los fármacos , Anfetaminas/administración & dosificación , Animales , Compuestos Bicíclicos con Puentes/administración & dosificación , Compuestos Bicíclicos con Puentes/farmacología , Relación Dosis-Respuesta a Droga , Alucinógenos/administración & dosificación , Inyecciones Intraperitoneales , Ketamina/farmacología , Dietilamida del Ácido Lisérgico/administración & dosificación , Masculino , Metilaminas/administración & dosificación , Metilaminas/farmacología , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Piperazinas/administración & dosificación , Piperazinas/farmacología , Pirazinas/administración & dosificación , Pirazinas/farmacología , Ratas , Ratas Wistar , Receptor de Serotonina 5-HT2A/metabolismo , Antagonistas de la Serotonina/farmacología , Agonistas de Receptores de Serotonina/administración & dosificación , Agonistas de Receptores de Serotonina/farmacologíaRESUMEN
Systemic administration of NMDA receptor antagonists, used to model schizophrenia, increase the power of high-frequency oscillations (130-180Hz, HFO) in a variety of neuroanatomical and functionally distinct brain regions. However, it is unclear whether HFO are independently and locally generated or instead spread from a distant source. To address this issue, we used local infusion of tetrodotoxin (TTX) to distinct brain areas to determine how accurately HFO recorded after injection of NMDAR antagonists reflect the activity actually generated at the electrode tip. Changes in power were evaluated in local field potentials (LFPs) recorded from the nucleus accumbens (NAc), prefrontal cortex and caudate and in electrocorticograms (ECoGs) from visual and frontal areas. HFO recorded in frontal and visual cortices (ECoGs) or in the prefrontal cortex, caudate (LFPs) co-varied in power and frequency with observed changes in the NAc. TTX infusion to the NAc immediately and profoundly reduced the power of accumbal HFO which correlated with changes in HFO recorded in distant cortical sites. In contrast, TTX infusion to the prefrontal cortex did not change HFO power recorded locally, although gamma power was reduced. A very similar result was found after TTX infusion to the caudate. These findings raise the possibility that the NAc is an important neural generator. Our data also support existing studies challenging the idea that high frequencies recorded in LFPs are necessarily generated at the recording site.
Asunto(s)
Ondas Encefálicas/efectos de los fármacos , Encéfalo/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Análisis de Varianza , Animales , Encéfalo/fisiología , Maleato de Dizocilpina/farmacología , Electrodos Implantados , Electroencefalografía , Agonistas de Aminoácidos Excitadores/farmacología , Análisis de Fourier , Masculino , N-Metilaspartato/farmacología , Vías Nerviosas/efectos de los fármacos , Vías Nerviosas/fisiología , Ratas , Ratas Wistar , Receptores de N-Metil-D-Aspartato/metabolismo , Bloqueadores de los Canales de Sodio/farmacología , Estadística como Asunto , Tetrodotoxina/farmacologíaRESUMEN
Improved understanding of the actions of antipsychotic compounds is critical for a better treatment of schizophrenia. Abnormal oscillatory activity has been found in schizophrenia and in rat models of the disease. N-Methyl-D-aspartic acid receptor (NMDAR) antagonists, used to model certain features of schizophrenia, increase the frequency and power of high-frequency oscillations (HFO, 130-180 Hz) in the rat nucleus accumbens, a brain region implicated in schizophrenia pathology. Antipsychotics can be classified as first- and second-generation drugs, the latter often reported to have wider benefit in humans and experimental models. This prompted the authors to examine the pre- and post-treatment effects of clozapine, risperidone (second-generation drugs) and sulpiride and haloperidol (first-generation drugs) on ketamine and MK801-enhanced accumbal HFO. Both NMDAR antagonists increased HFO frequency. In contrast, clozapine and risperidone markedly and dose-dependently reduced the frequency of spontaneous and NMDAR-antagonist-enhanced HFO, whilst a moderate effect was found for sulpiride and a much weaker effect for haloperidol. Unexpectedly, we found reductions in HFO frequency were associated with an increase in its power. These findings indicate that modulation of accumbal HFO frequency may be a fundamental effect produced by antipsychotic compounds. Of the drugs investigated, first- and second-generation compounds could be dissociated by their potency on this measure. This effect may partially explain the differences in the clinical profile of these drugs.
Asunto(s)
Antipsicóticos/uso terapéutico , Relojes Biológicos/efectos de los fármacos , Núcleo Accumbens/fisiología , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/fisiopatología , Animales , Antipsicóticos/farmacología , Modelos Animales de Enfermedad , Maleato de Dizocilpina/uso terapéutico , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica/efectos adversos , Electroencefalografía , Antagonistas de Aminoácidos Excitadores/toxicidad , Ketamina/toxicidad , Locomoción/efectos de los fármacos , Masculino , Núcleo Accumbens/efectos de los fármacos , Ratas , Ratas Wistar , Esquizofrenia/inducido químicamente , Factores de TiempoRESUMEN
Ketamine, phencyclidine and MK801 are uncompetitive NMDA receptor (NMDAR) antagonists which are used widely to model certain features of schizophrenia in rats. Systemic administration of NMDAR antagonists, in addition to provoking an increase in c-Fos expression, leads to important neurochemical and electrophysiological changes within the medial prefrontal cortex (mPFC). Since the mPFC is considered to exert a top-down regulatory control of subcortical brain regions, we examined the effects of local infusion of the NMDAR antagonist, MK801, into the mPFC on the expression of c-Fos protein (widely used marker of neuronal activation) in several subcortical structures. The experiment was performed on freely moving rats, bilaterally implanted with guide cannulae in the prelimbic mPFC, infused with MK801 or saline. Bilateral administration of MK801 to the mPFC produced changes in the behavior (increased stereotypy and decreased sleep-like behavior) and complex changes in c-Fos protein expression with significant increases observed in the nucleus accumbens (core and shell), amygdala (basolateral and central nuclei), the CA1 field of the hippocampus, and mediodorsal and paraventricular thalamic nuclei, as compared to the saline group. Together, we demonstrate that blockade of NMDA receptors in the mPFC is sufficient to lead to behavioral abnormalities and increased c-Fos expression in many, but not all, of the subcortical structures examined. Our findings suggest that some of the behavioral abnormalities produced by uncompetitive NMDAR antagonists may result from aberrant activity in cortico-subcortical pathways. These data support an increasing body of literature, suggesting that the mPFC is an important site mediating the effects of NMDAR antagonists.
Asunto(s)
Encéfalo/metabolismo , Corteza Prefrontal/fisiología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Análisis de Varianza , Animales , Encéfalo/anatomía & histología , Maleato de Dizocilpina/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Masculino , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Vías Nerviosas/efectos de los fármacos , Vías Nerviosas/fisiología , Corteza Prefrontal/efectos de los fármacos , Ratas , Ratas WistarRESUMEN
Previously, we showed that NMDA antagonists enhance high-frequency oscillations (130-180 Hz) in the nucleus accumbens. However, whether NMDA antagonists can enhance high-frequency oscillations in other brain regions remains unclear. Here, we used monopolar, bipolar and inverse current source density techniques to examine oscillatory activity in the hippocampus, a region known to generate spontaneous ripples (â¼200 Hz), its surrounding tissue, and the dorsal striatum, neuroanatomically related to the nucleus accumbens. In monopolar recordings, ketamine-induced increases in the power of high-frequency oscillations were detected in all structures, although the power was always substantially larger in the nucleus accumbens. In bipolar recordings, considered to remove common-mode input, high-frequency oscillations associated with ketamine injection were not present in the regions we investigated outside the nucleus accumbens. In line with this, inverse current source density showed the greatest changes in current to occur in the vicinity of the nucleus accumbens and a monopolar structure of the generator. We found little spatial localisation of ketamine high-frequency oscillations in other areas. In contrast, sharp-wave ripples, which were well localized to the hippocampus, occurred less frequently after ketamine. Notably, we also found ketamine produced small, but significant, changes in the power of 30-90 Hz gamma oscillations (an increase in the hippocampus and a decrease in the nucleus accumbens).
Asunto(s)
Ondas Encefálicas/efectos de los fármacos , Cuerpo Estriado/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Hipocampo/efectos de los fármacos , Ketamina/farmacología , Núcleo Accumbens/efectos de los fármacos , Animales , Ondas Encefálicas/fisiología , Cuerpo Estriado/fisiología , Hipocampo/fisiología , Masculino , Núcleo Accumbens/fisiología , Ratas , Ratas WistarRESUMEN
The pedunculopontine tegmental nucleus (PPN), as a part of reticular formation activating system, is thought to be involved in the sleep/wake cycle regulation, and plays an important role in the generation and regulation of hippocampal rhythmical slow activity. The activity of PPN can be modulated by serotonergic system, mainly through multiple projections from raphe nuclei, which can influence PPN neurons through different classes of 5-HT receptors. In the present study, the effect of intra-PPN injection of two serotonin agonists: 8-OH-DPAT and 5-CT, on hippocampal formation EEG activity was examined in urethane-anesthetized rats. The study found that the microinjections induced prolonged spontaneous theta rhythm in both hippocampi with a short latency. The results obtained suggest that local inhibition of presumably cholinergic neurons in the PPN acts as a trigger for hippocampal theta activity.
Asunto(s)
Hipocampo , Núcleo Tegmental Pedunculopontino , Agonistas de Receptores de Serotonina/farmacología , Serotonina/farmacología , Ritmo Teta/efectos de los fármacos , 8-Hidroxi-2-(di-n-propilamino)tetralin/farmacología , Animales , Electroencefalografía/efectos de los fármacos , Hipocampo/efectos de los fármacos , Hipocampo/fisiología , Masculino , Microinyecciones , Núcleo Tegmental Pedunculopontino/efectos de los fármacos , Núcleo Tegmental Pedunculopontino/fisiología , Núcleos del Rafe/citología , Núcleos del Rafe/fisiología , Ratas , Ratas Wistar , Receptores de Serotonina/metabolismo , Ritmo Teta/fisiologíaRESUMEN
We reported recently that ketamine can increase the power of high-frequency oscillations (HFO) in the rodent nucleus accumbens (NAc), a region implicated in the pathophysiology of schizophrenia. Lamotrigine is known to reduce several of the abnormal behaviors induced by NMDA receptor antagonists in humans and rodents. This prompted us to examine whether lamotrigine would disrupt ketamine-enhanced HFO. Local field potentials (LFPs) and locomotor activity were recorded from male Wistar rats chronically implanted with electrodes in the NAc. Rats were pretreated with either saline or lamotrigine for 60min followed by injection of ketamine (25mg/kg). A separate group received a unilateral intra-NAc infusion of lamotrigine immediately followed by systemic injection of ketamine. We found systemic injection of a high dose of lamotrigine (20.1mg/kg) reduced the power and frequency of ketamine-enhanced HFO. This dose of lamotrigine was also associated with a decrease in both spontaneous HFO and locomotor activity, but did not significantly reduce locomotor activity induced by ketamine. In contrast, a low dose of lamotrigine (2.0mg/kg) produced a small, but significant increase of both ketamine-enhanced HFO and locomotor activity. Local infusion of lamotrigine into the NAc did not significantly affect ketamine-induced HFO, suggesting lamotrigine produces its effect on structures afferent to the NAc, and effects on HFO most likely result from modulating excitatory transmission to the NAc.
Asunto(s)
Antagonistas de Aminoácidos Excitadores/farmacología , Ventilación de Alta Frecuencia , Potenciales de la Membrana/efectos de los fármacos , Núcleo Accumbens/efectos de los fármacos , Triazinas/farmacología , Algoritmos , Análisis de Varianza , Animales , Relación Dosis-Respuesta a Droga , Electroencefalografía , Ketamina/farmacología , Lamotrigina , Masculino , Microinyecciones , Actividad Motora/efectos de los fármacos , Núcleo Accumbens/fisiología , Ratas , Ratas Wistar , Análisis Espectral , Factores de TiempoRESUMEN
The R6/2 transgenic mouse model of Huntington's disease (HD) develops a progressive neurological phenotype that involves severe motor and cognitive dysfunctions. Although not a cardinal sign, diabetes has been described in R6/2 mice. It is not clear, however, whether the diabetes contributes to the HD-like phenotype of R6/2 mice. In our study we found that the severity of diabetes in R6/2 mice was associated with the progressive formation of ubiquinated inclusions in pancreatic beta cells. Diabetes is dissociated from early motor and cognitive dysfunctions and did not correlate with motor impairment and survival of R6/2 mice. However, chronic behavioural testing (at a level higher than that which is reported to improve several aspects of the R6/2 phenotype) exacerbated the onset of diabetes. Pharmacological treatment of the diabetes was attempted using two oral hypoglycaemic agents commonly used by diabetics. The mice responded acutely to glibenclamide (which induces exocytosis of insulin) but not to rosiglitazone (which induces sensitization to insulin). This supports the suggestion that the diabetes in R6/2 mice is caused by an impairment in insulin release rather than insulin insensitivity. However, chronic treatment with these hypoglycaemic agents had no effect on either the course of the diabetes or the disease in R6/2 mice.
Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Intolerancia a la Glucosa/tratamiento farmacológico , Gliburida/farmacología , Enfermedad de Huntington/complicaciones , Hipoglucemiantes/farmacología , Administración Oral , Animales , Conducta Animal , Diabetes Mellitus/genética , Diabetes Mellitus/patología , Modelos Animales de Enfermedad , Exocitosis/efectos de los fármacos , Intolerancia a la Glucosa/genética , Intolerancia a la Glucosa/patología , Glucosuria/tratamiento farmacológico , Glucosuria/genética , Glucosuria/patología , Enfermedad de Huntington/genética , Insulina/metabolismo , Células Secretoras de Insulina/efectos de los fármacos , Células Secretoras de Insulina/metabolismo , Células Secretoras de Insulina/patología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Ratones Mutantes Neurológicos , Ratones Transgénicos , Rosiglitazona , Tiazolidinedionas/farmacologíaRESUMEN
Huntington's disease is a genetic disease caused by a single mutation. It is characterized by progressive movement, emotional and cognitive deficits. R6/2 mice transgenic for exon 1 of the HD gene with 150+ CAG repeats have a progressive neurological phenotype, including deterioration in cognitive function. The mechanism underlying the cognitive deficits in R6/2 mice is unknown, but dysregulated gene expression, reduced neurotransmitter levels and abnormal synaptic function are present before the cognitive decline becomes pronounced. Our goal here was to ameliorate the cognitive phenotype in R6/2 mice using a combination drug therapy (tacrine, moclobemide and creatine) aimed at boosting neurotransmitter levels in the brain. Treatment from 5 weeks of age prevented deterioration in two different cognitive tasks until at least 12 weeks. However, motor deterioration continued unabated. Microarray analysis of global gene expression revealed that many genes significantly up- or down-regulated in untreated R6/2 mice had returned towards normal levels after treatment, though a minority were further dysregulated. Thus dysregulated gene expression was reversed by the combination treatment in the R6/2 mice and probably underlies the observed improvements in cognitive function. Our study shows that cognitive decline caused by a genetic mutation can be slowed by a combination drug treatment, and gives hope that cognitive symptoms in HD can be treated.
Asunto(s)
Trastornos del Conocimiento/tratamiento farmacológico , Enfermedad de Huntington/tratamiento farmacológico , Nootrópicos/uso terapéutico , Factores de Edad , Animales , Peso Corporal/efectos de los fármacos , Química Encefálica/efectos de los fármacos , Trastornos del Conocimiento/etnología , Trastornos del Conocimiento/orina , Modelos Animales de Enfermedad , Quimioterapia Combinada , Expresión Génica/efectos de los fármacos , Glucosa/metabolismo , Enfermedad de Huntington/complicaciones , Enfermedad de Huntington/orina , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Neurotransmisores/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos/métodos , Fenotipo , ARN Mensajero/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Prueba de Desempeño de Rotación con Aceleración Constante/métodos , Conducta Espacial/fisiología , Conducta Espacial/efectos de la radiación , Repeticiones de Trinucleótidos/genéticaRESUMEN
Noncompetitive NMDA receptor antagonists, such as ketamine, induce a transient schizophrenia-like state in healthy individuals and exacerbate psychosis in schizophrenic patients. In rodents, noncompetitive NMDA receptor antagonists induce a behavioral syndrome that represents an experimentally valid model of schizophrenia. Current experimental evidence has implicated the nucleus accumbens in the pathophysiology of schizophrenia and the psychomimetic actions of ketamine. In this study, we have demonstrated that acute systemic administration of ketamine, at a dose known to produce hyperlocomotion and stereotypy, depressed the amplitude of the monosynaptic component of fimbria-evoked field potentials recorded in the nucleus accumbens. A similar effect was observed using the more selective antagonist dizocilpine maleate, indicating the depression was NMDA receptor dependent. Paired-pulse facilitation was enhanced concomitantly with, and in proportion to, ketamine-induced depressed synaptic efficacy, indicative of a presynaptic mechanism of action. Notably, the depression of field potentials recorded in the nucleus accumbens was markedly reduced after a focal 6-hydroxydopamine lesioning procedure in the nucleus accumbens. More specifically, pretreatment with the D2/D4 antagonist haloperidol, but not the D1 antagonist SCH23390 blocked ketamine-induced depression of nucleus accumbens responses. Our findings provide supporting evidence for the contemporary theory of schizophrenia as aberrant excitatory neurotransmission at the level of the nucleus accumbens.
Asunto(s)
Dopamina/fisiología , Hipocampo/fisiología , Ketamina/farmacología , Núcleo Accumbens/fisiología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Esquizofrenia/fisiopatología , Animales , Modelos Animales de Enfermedad , Estimulación Eléctrica , Potenciales Evocados/efectos de los fármacos , Potenciales Evocados/fisiología , Fórnix/fisiología , Ácido Glutámico/metabolismo , Masculino , Vías Nerviosas/fisiología , Plasticidad Neuronal/efectos de los fármacos , Plasticidad Neuronal/fisiología , Ratas , Ratas Wistar , Receptores de N-Metil-D-Aspartato/fisiología , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiologíaRESUMEN
Stress-related alterations to the induction of hippocampal synaptic plasticity have been implicated in certain forms of psychiatric disorders. However, relatively little is known about such changes in other psychiatric disorders-related structures. We tested this possibility in one of such structures, the nucleus accumbens, during re-exposure of rats to a conditioned stressful environment, in which they had previously received shock. In both control rats (no shock) and shocked rats previously submitted to an extensive pre-exposure to the to-be-conditioned contextual cues (latent inhibition), high- and low-frequency stimulation of fimbria-accumbens pathway induced, in the nucleus accumbens, similar pattern of increases and decreases in synaptic efficacy, respectively. However, in non-pre-exposed shocked rats, re-exposure to the conditioned contextual cues evoked high levels of freezing, which was accompanied by a blockade of the induction of enhancement, but a facilitation of the depression, of synaptic efficacy. In addition, contextual conditioning did not alter the baseline transmission whatever the stimulus intensity and was ineffective on the induction of fimbria-accumbens synaptic plasticity following complete extinction of freezing response to the conditioned contextual cues. These data support the idea according to which stress may be involved in certain forms of psychiatric disorders via induction of metaplastic changes in circuits including the hippocampus and hippocampal limbic target structures such as the nucleus accumbens.